Women’s Health News

About one in 11 women with cesarean deliveries at 34 weeks’ gestation or longer developed PTSD symptoms 2 months later, according to study results published in the American Journal of Obstetrics and Gynecology.

The Dobbs decision was associated with declines in prescriptions for oral contraceptive pills, especially for emergency contraception, in states with the most restrictive abortion laws, according to cohort study results.

SAN FRANCISCO — AI has evolved rapidly in the past few years, and with this comes generative AI, which creates content based on short prompts and plentiful data that might be useful in health care while also posing some trade-offs.

Postpartum readmission risk was higher for women with stillbirth vs. live birth deliveries, with mental health/substance use disorders and thromboembolism accounting for more, and hypertension fewer, readmissions following stillbirth.

There was a nearly 13% increase infant deaths in Texas after the state implemented a ban on abortion in early pregnancy in 2021, according to research published in JAMA Pediatrics.

Obtaining medication abortion after no-test telehealth screening and mail-order medication dispensing was tied to similar abortion completion rates as in-person care with ultrasonography, according to study results published in JAMA.

Depressive symptoms during pregnancy may indicate elevated cardiovascular risk for women, especially hypertension, ischemic heart disease and heart failure, according to a study published in the European Heart Journal.

Women with chronic pelvic pain have more ED visits, imaging tests and hysterectomies and higher rates of overlapping chronic pain conditions vs. women without chronic pelvic pain, according to findings published in Obstetrics & Gynecology.

Noting that practice varies widely across hospitals, an expert panel came to a consensus on the first quality indicators for the care of opioid-exposed infants.

Lenacapavir, an injectable antiretroviral drug approved by the FDA for HIV treatment, prevented 100% of new HIV infections among women in a phase 3 trial in Africa, demonstrating its efficacy as PrEP, Gilead Sciences said.